Precision oncology matches each patient with the therapy most likely to work, based on the molecular profile of their tumor. For molecular labs, that means turning somatic NGS data into reliable, actionable results: detecting SNVs, indels and CNVs, and assessing genomic signatures such as HRD, MSI and TMB that guide treatment decisions.
In this section, we share our latest articles on precision oncology: case studies from labs using SeqOne for somatic analysis, scientific insights on biomarkers like homologous recombination deficiency, and updates on how our platform helps teams deliver faster, clinically validated cancer reports.

Jonathan Sheldon, a distinguished bioinformatics and digital health executive (ex-QIAGEN, Oracle), joins SeqOne's board, bolstering their global personalized medicine expansion.
New capital from Supernova Invest, alongside existing partners Elaia, Omnes, and Merieux Equity Partners, will accelerate SeqOne’s mission to transform genomic diagnostics worldwide, focusing on international expansion, U.S., and strategic growth.
SeqOne's SomaHemato offers robust, validated IGHV analysis for CLL prognosis, overcoming NGS short-read limits for precise clinical insights.

The evolution of next-generation sequencing (NGS) technologies has led to increased focus on RNA-Seq. Many bioinformatic tools have been developed for RNA-Seq analysis, each with unique performance characteristics and configuration parameters.

The huge body of publicly available RNA-sequencing (RNA-seq) libraries is a treasure of functional information allowing to quantify the expression of known or novel transcripts in tissues.